Cargando…

Fuzzy optimization for identifying antiviral targets for treating SARS-CoV-2 infection in the heart

In this paper, a fuzzy hierarchical optimization framework is proposed for identifying potential antiviral targets for treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the heart. The proposed framework comprises four objectives for evaluating the elimination of vira...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chu, Sz-Wei, Wang, Feng-Sheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10537911/ https://www.ncbi.nlm.nih.gov/pubmed/37759157 http://dx.doi.org/10.1186/s12859-023-05487-7

Ejemplares similares

Human/SARS-CoV-2 genome-scale metabolic modeling to discover potential antiviral targets for COVID-19
por: Wang, Feng-Sheng, et al.
Publicado: (2022)

Identification of the SARS-unique domain of SARS-CoV-2 as an antiviral target
por: Qin, Bo, et al.
Publicado: (2023)

Author's overview: identifying SARS-CoV-2 antiviral compounds
por: Diffley, John F.X.
Publicado: (2021)

SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries
por: Elshabrawy, Hatem A.
Publicado: (2020)

SARS-CoV-2 RNA polymerase as target for antiviral therapy
por: Buonaguro, Luigi, et al.
Publicado: (2020)

SARS-CoV-2 cell entry and targeted antiviral development
por: Chen, Zinuo, et al.
Publicado: (2021)

SARS-CoV-2 Antiviral Therapy
por: Tao, Kaiming, et al.
Publicado: (2021)

Targeting SARS-CoV-2 using polycomb inhibitors as antiviral agents
por: Ayaz, Sameer, et al.
Publicado: (2020)

Targeting SARS-CoV-2 Proteases for COVID-19 Antiviral Development
por: Lv, Zongyang, et al.
Publicado: (2022)

Antiviral cyclic peptides targeting the main protease of SARS-CoV-2
por: Johansen-Leete, Jason, et al.
Publicado: (2022)

Potential antiviral peptides targeting the SARS-CoV-2 spike protein
por: Khater, Ibrahim, et al.
Publicado: (2022)

Aminoglycosides and their potential as SARS-CoV-2 antivirals
por: Cimolai, Nevio
Publicado: (2021)

SARS-CoV-2 rebound with and without antivirals
por: Petrosillo, Nicola
Publicado: (2023)

Antiviral drugs against SARS-CoV-2
por: Aiello, Tommaso Francesco, et al.
Publicado: (2022)

Antiviral peptides against SARS-CoV-2: therapeutic targets, mechanistic antiviral activity, and efficient delivery
por: Essa, Raahilah Zahir, et al.
Publicado: (2022)

QTc interval prolongation in patients infected with SARS-CoV-2 and treated with antiviral drugs()()
por: Esmel-Vilomara, Roger, et al.
Publicado: (2022)

In silico design of antiviral peptides targeting the spike protein of SARS-CoV-2
por: Ling, Rongsong, et al.
Publicado: (2020)

Development of targeted nanoparticles loaded with antiviral drugs for SARS-CoV-2 inhibition
por: Sanna, Vanna, et al.
Publicado: (2022)

The discovery of antivirals and novel targets for SARS-CoV-2 and EV-A71
por: Haddad, Christina, et al.
Publicado: (2022)

Clinical Trials of Repurposed Antivirals for SARS-CoV-2
por: Martinez, Miguel Angel
Publicado: (2020)

SARS-CoV-2 and the Use of Chloroquine as an Antiviral Treatment
por: Rebeaud, Mathieu E., et al.
Publicado: (2020)

Host proviral and antiviral factors for SARS-CoV-2
por: Lv, Lu, et al.
Publicado: (2021)

Mechanisms of Antiviral Immune Evasion of SARS-CoV-2
por: Beyer, Daniel K., et al.
Publicado: (2022)

Antiviral Effect of Budesonide against SARS-CoV-2
por: Heinen, Natalie, et al.
Publicado: (2021)

Theory and reality of antivirals against SARS-CoV-2
por: Zhao, Bo, et al.
Publicado: (2021)

Antiviral Efficacy of Pralatrexate against SARS-CoV-2
por: Bae, Joon-Yong, et al.
Publicado: (2021)

Optimization of Triarylpyridinone Inhibitors of the Main Protease of SARS-CoV-2 to Low-Nanomolar Antiviral Potency
por: Zhang, Chun-Hui, et al.
Publicado: (2021)

Identifying Innate Resistance Hotspots for SARS-CoV-2 Antivirals Using In Silico Protein Techniques
por: Portelli, Stephanie, et al.
Publicado: (2023)

Antiviral Properties of the NSAID Drug Naproxen Targeting the Nucleoprotein of SARS-CoV-2 Coronavirus
por: Terrier, Olivier, et al.
Publicado: (2021)

Genome-wide characterization of SARS-CoV-2 cytopathogenic proteins in the search of antiviral targets
por: Zhang, Jiantao, et al.
Publicado: (2021)

Genome-Wide Characterization of SARS-CoV-2 Cytopathogenic Proteins in the Search of Antiviral Targets
por: Zhang, Jiantao, et al.
Publicado: (2022)

SARS-CoV-2-mediated dysregulation of metabolism and autophagy uncovers host-targeting antivirals
por: Gassen, Nils C., et al.
Publicado: (2021)

Identification of multi-targeting natural antiviral peptides to impede SARS-CoV-2 infection
por: Singh, Satyendra, et al.
Publicado: (2022)

The heart and SARS-CoV-2
por: González-Calle, David, et al.
Publicado: (2022)

Identification of novel antiviral drug candidates using an optimized SARS-CoV-2 phenotypic screening platform
por: Bojkova, Denisa, et al.
Publicado: (2023)

Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp15 endoribonuclease
por: Canal, Berta, et al.
Publicado: (2021)

Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp13 helicase
por: Zeng, Jingkun, et al.
Publicado: (2021)

Fluoroquinolone Antibiotics Exhibit Low Antiviral Activity against SARS-CoV-2 and MERS-CoV
por: Scroggs, Stacey L. P., et al.
Publicado: (2020)

Potential Antiviral Options against SARS-CoV-2 Infection
por: Ianevski, Aleksandr, et al.
Publicado: (2020)

Potent antiviral effect of silver nanoparticles on SARS-CoV-2
por: Jeremiah, Sundararaj S., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7t4vsd1n1fe0idqq4mt227rhtm